Zavzpret (zavegepant) NDC 63539-135

NDC codes

FDA NDC Directory

Product NDC (as listed)63539-135Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63539-0135Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63539-135-02	63539013502	1 BLISTER PACK in 1 CARTON (63539-135-02) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK (63539-135-01) / .1 mL in 1 VIAL, SINGLE-DOSEMarketed from Jun 1, 2023 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zavzpret
Generic name (nonproprietary): zavegepant
Active ingredients: Zavegepant hydrochloride — 10 mg/.1mL
Dosage form: Spray
Route: Nasal
Labeler: U.S. Pharmaceuticals
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 216386
Marketing start: Jun 1, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Calcitonin Gene-related Peptide Receptor Antagonists (Mechanism)
Identifiers: Product ID 63539-135_3f4a6bba-ce03-463b-9167-65580312987fSPL ID 3f4a6bba-ce03-463b-9167-65580312987fSPL set ID 1191475f-e999-49f4-a805-93ad08596b1bRxCUI 2637974, 2637980UNII 000QCM6HAL
Pharmacologic class: Calcitonin Gene-related Peptide Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463539013502 followed by a unit qualifier and the quantity

Package 63539-0135-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 26, 2025.

Indications (excerpt from the label)

ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 216386

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 216386
Product	Strength	Form · route	Labeler	Product NDC
Zavzpretzavegepant	Zavegepant hydrochloride 10 mg/.1mL	SprayNasal	Pfizer Laboratories Div Pfizer Inc	0069-3500